BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12855110)

  • 1. Effect of polyethyleneglycol (PEG) chain on cell uptake of PEG-modified liposomes.
    Sadzuka Y; Kishi K; Hirota S; Sonobe T
    J Liposome Res; 2003 May; 13(2):157-72. PubMed ID: 12855110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization and cytotoxicity of mixed PEG-DSG modified liposomes].
    Sadzuka Y; Tsuruda T; Sonobe T
    Yakugaku Zasshi; 2005 Jan; 125(1):149-57. PubMed ID: 15635286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hybridized liposome by novel modification with some polyethyleneglycol-lipids.
    Sugiyama I; Sonobe T; Sadzuka Y
    Int J Pharm; 2009 May; 372(1-2):177-83. PubMed ID: 19429278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in the character of liposomes as a drug carrier by modifying various polyethyleneglycol-lipids.
    Sugiyama I; Sadzuka Y
    Biol Pharm Bull; 2013; 36(6):900-6. PubMed ID: 23727913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome.
    Sadzuka Y; Nakade A; Hirama R; Miyagishima A; Nozawa Y; Hirota S; Sonobe T
    Int J Pharm; 2002 May; 238(1-2):171-80. PubMed ID: 11996821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin.
    Sadzuka Y; Sugiyama I; Tsuruda T; Sonobe T
    Int J Pharm; 2006 Apr; 312(1-2):83-9. PubMed ID: 16457972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin.
    Sadzuka Y; Nakade A; Tsuruda T; Sonobe T
    J Control Release; 2003 Sep; 91(3):271-80. PubMed ID: 12932707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake?
    Sadzuka Y; Hirota S
    Cancer Lett; 1998 Sep; 131(2):163-70. PubMed ID: 9851249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
    Sugiyama I; Sadzuka Y
    Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin.
    Sadzuka Y; Nakai S; Miyagishima A; Nozawa Y; Hirota S
    Cancer Lett; 1997 Jan; 111(1-2):77-86. PubMed ID: 9022131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
    Klibanov AL; Maruyama K; Beckerleg AM; Torchilin VP; Huang L
    Biochim Biophys Acta; 1991 Feb; 1062(2):142-8. PubMed ID: 2004104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dose on the distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes.
    Sadzuka Y; Nakai S; Miyagishima A; Nozawa Y; Hirota S
    J Drug Target; 1995; 3(1):31-7. PubMed ID: 7655818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced distribution and anti-tumor activity of ergosta-4,6,8(14),22-tetraen-3-one by polyethylene glycol liposomalization.
    Sun Y; Ji Z; Zhao Y; Liang X; Hu X; Fan J
    J Nanosci Nanotechnol; 2013 Feb; 13(2):1435-9. PubMed ID: 23646655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
    Yoshizawa Y; Kono Y; Ogawara K; Kimura T; Higaki K
    Int J Pharm; 2011 Jun; 412(1-2):132-41. PubMed ID: 21507344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
    Sadzuka Y; Hirotsu S; Hirota S
    Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes.
    Sugiyama I; Sadzuka Y
    Curr Drug Discov Technol; 2011 Dec; 8(4):357-66. PubMed ID: 22034853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
    Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
    Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [To Assess Drug Delivery System Nanocarrier at Industrial Production: Establishment of Liposomal Surface Using Physicochemical Properties].
    Sadzuka Y
    Yakugaku Zasshi; 2024; 144(1):61-69. PubMed ID: 38171797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.
    Webb MS; Saxon D; Wong FM; Lim HJ; Wang Z; Bally MB; Choi LS; Cullis PR; Mayer LD
    Biochim Biophys Acta; 1998 Jul; 1372(2):272-82. PubMed ID: 9675310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.